Developer docs
API playgroundTry for free, no card

Search company profiles

Cycle Pharmaceuticals

Full company profile

uuid0000h4p

Namestring
Cycle Pharmaceuticals
Legal namestring
Cycle Pharmaceuticals Limited
Websiteurl
cyclepharma.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Cycle Pharmaceuticals is a UK-headquartered, privately-held specialty pharmaceutical company founded in 2012 by James Harrison to develop and commercialize treatments for rare and ultra-rare diseases. The company operates from Cambridge, UK, with US offices in Detroit and Boston, and employs over 100 people across multiple nationalities. Cycle has assembled a portfolio of 10 FDA-approved products spanning oncology (PHYRAGO/dasatinib, CAVHANZA/nilotinib ODT), neurology (TASCENSO ODT/fingolimod, BAFIERTAM/monomethyl fumarate), metabolics (NITYR/nitisinone, HARLIKU/nitisinone, JAVYGTOR/sapropterin), immunology (SAJAZIR/icatibant), and urology/nephrology (VENXXIVA/tiopronin, ORMALVI/dichlorphenamide).

Cycle's core technical capability is drug reformulation — applying technologies including orally disintegrating tablet (ODT) formulations via Catalent's ZYDIS platform and Flex Pharma's ElectroNanoSpray (ENS) platform to improve form factor, swallowability, and co-medication compatibility (notably acid-reducing agent compatibility for TKIs). The company's commercial model relies on US specialty pharmacy distribution through exclusive partners (Onco360, LeMed, Anovo) and the three major US pharmaceutical distributors (McKesson, Cencora, Cardinal Health). Patient engagement is anchored by the Cycle Vita support hub providing financial, clinical, and adherence services, supplemented by the AI-enabled Cycle Vita PKU app. Internationally, Cycle operates a Free Goods Programme in 15 countries via partner Inceptua, embedding patient access in the company's constitutional documents. Recent M&A (Banner Life Sciences in January 2025, Applied Therapeutics in February 2026) has expanded the neurology and CNS rare metabolic disease franchises respectively.

Short descriptiontext

Cycle Pharmaceuticals is a UK-headquartered rare disease pharmaceutical company founded in 2012 that develops and commercializes 10 FDA-approved treatments across oncology, neurology, metabolics, and immunology, distributed via US specialty pharmacy networks and supported by the Cycle Vita patient hub.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease pharmaceuticals, specialty pharma distribution, orally disintegrating tablets, patient support services, branded drug reformulation
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Rare Disease)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Cycle Pharmaceuticals generates revenue through the sale of FDA-approved pharmaceutical products for rare diseases and oncology. The company commercializes branded drugs across multiple therapeutic areas (metabolic, immunological, neurological, oncology) through specialty pharmacy distribution networks in the US market, complemented by patient support programs.

cyclepharma.com
2Free Goods Programme
TypeProfessional Services
Description

Cycle operates a Free Goods Programme (Special Access Scheme/Compassionate Use Programme) providing nitisinone to patients with HT-1 and AKU in countries where they are unlikely to have means to pay, at no cost to patients. This is embedded in the company's constitutional documents and represents a non-revenue charitable program.

cyclepharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Cycle Vita
Description

Patient support programme for patients in the US providing individualized emotional, financial, and product support.

cyclepharma.com
+1 more record
Core offering1 text field

Cycle Pharmaceuticals develops, reformulates, and commercializes FDA-approved pharmaceutical products for rare and ultra-rare diseases across oncology, neurology, metabolics, and immunology. The company distributes branded therapies (e.g., NITYR, HARLIKU, PHYRAGO, CAVHANZA, TASCENSO ODT, BAFIERTAM, SAJAZIR, JAVYGTOR, ORMALVI, VENXXIVA) through specialty pharmacy networks in the US and supplements its commercial offering with the Cycle Vita patient support programme and an international Free Goods Programme.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • HARLIKU (nitisinone) reduces urinary homogentisic acid (HGA) production by up to 97% in AKU patients
+3 more records
Product overview1 text field

Cycle Pharmaceuticals is a rare disease-focused pharmaceutical company offering a portfolio of treatments across oncology, neurology/metabolics, immunology, and urology. The company operates as a single-brand pharmaceutical manufacturer with patient support services. Core products include NITYR (nitisinone) for HT-1, SAJAZIR (icatibant) for HAE, JAVYGTOR (sapropterin) for PKU, TASCENSO ODT (fingolimod) for MS, BAFIERTAM (monomethyl fumarate) for MS, ORMALVI (dichlorphenamide) for periodic paralysis, VENXXIVA (tiopronin) for cystinuria, and HARLIKU (nitisinone) for AKU. In oncology, the portfolio includes PHYRAGO (dasatinib) for Ph+ leukemias and CAVHANZA (nilotinib) for Ph+ CML. The company also provides the Cycle Vita™ patient support platform including a PKU management app. Following the 2026 acquisition of Applied Therapeutics, the pipeline expanded to include govorestat for CNS rare metabolic diseases.

Product and service12 records
1PHYRAGO (dasatinib) Tablets
CategoryOncology pharmaceuticals
Description

Tyrosine kinase inhibitor tablet for adults and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). Bioequivalent to Sprycel with the unique clinical benefit of allowing co-administration with proton pump inhibitors and H2 receptor antagonists.

2CAVHANZA (nilotinib) Orally Disintegrating Tablets
CategoryOncology pharmaceuticals
Description

Orally disintegrating kinase inhibitor tablet for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed adults in chronic phase and adults with chronic and accelerated phase Ph+ CML resistant or intolerant to prior therapy including imatinib. First nilotinib formulation allowing co-administration with acid-reducing agents without timing restrictions, using Flex Pharma's ElectroNanoSpray technology for improved solubility and dissolution.

3HARLIKU (nitisinone) Tablets
CategoryRare metabolic disease pharmaceuticals
Description

First and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients with alkaptonuria (AKU/Black Bone Disease). Reduces urinary HGA production by up to 97% through enzyme inhibition.

4BAFIERTAM (monomethyl fumarate) Delayed-Release Capsules
CategoryNeurology pharmaceuticals
Description

Disease-modifying therapy for relapsing forms of multiple sclerosis. A unique fumarate agent requiring no dietary restrictions and no metabolic conversion, acquired from Banner Life Sciences.

5TASCENSO ODT (fingolimod)
CategoryNeurology pharmaceuticals
Description

Sphingosine 1-phosphate receptor modulator for relapsing forms of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. First orally disintegrating tablet for MS patients, using Catalent ZYDIS technology.

6VENXXIVA (tiopronin) Delayed-Release Tablets
CategoryRare urology/nephrology pharmaceuticals
Description

Reducing and complexing thiol for prevention of cystine stone formation in patients with severe homozygous cystinuria. Available in 100mg and 300mg doses, to be taken without food.

7ORMALVI (dichlorphenamide) Tablets
CategoryRare neurology pharmaceuticals
Description

Oral carbonic anhydrase inhibitor for treatment of primary hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP), and related variants.

8SAJAZIR (icatibant) Injection
CategoryRare immunology pharmaceuticals
Description

Bradykinin B2 receptor antagonist for treatment of acute attacks of hereditary angioedema (HAE) in adults 18+. Self-administered subcutaneous injection delivering 30mg icatibant.

9JAVYGTOR (sapropterin dihydrochloride)
CategoryRare metabolic disease pharmaceuticals
Description

Treatment to reduce blood phenylalanine levels in patients with tetrahydrobiopterin-responsive Phenylketonuria (PKU). Available as 100mg tablets and 100mg/500mg powder for oral solution, used in conjunction with a Phe-restricted diet.

10NITYR (nitisinone) Tablets
CategoryRare metabolic disease pharmaceuticals
Description

Treatment for Hereditary Tyrosinemia Type 1 (HT-1), Cycle's original commercial product launched in 2017 and updated in 2018 for infant administration dosing.

11Cycle Vita Patient Support Program
CategoryPatient support services
Description

Comprehensive patient support hub providing individualized emotional, financial, and product support for patients on Cycle medications, including co-pay assistance, bridge programs, registered dietitian nutrition support, and the Cycle Vita PKU mobile app.

12Cycle Vita PKU Mobile App
CategoryPatient support mobile application
Description

Smartphone application for PKU management featuring medication and lab result tracking, diet management tools, and an AI-powered meal scanner for food identification and nutritional analysis. Available on iOS App Store and Google Play.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Cycle partnered with Flex Pharma for CAVHANZA (nilotinib) ODT formulation. Flex contributed its proprietary ElectroNanoSpray (ENS) platform technology to develop an improved nilotinib formulation with maintained bioavailability when taken with acid-reducing agents, addressing a significant unmet need in CML treatment.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-03
Description

Cycle completed the acquisition of Applied Therapeutics, a NASDAQ-listed clinical-stage biopharma focused on rare metabolic diseases. Applied's lead drug candidate govorestat (CNS-penetrant Aldose Reductase Inhibitor) targets Classic Galactosemia, CMT-SORD, and PMM2-CDG. The all-cash transaction was funded from Cycle's existing cash reserves.

3Handa Therapeutics, LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Cycle launched PHYRAGO (dasatinib) tablets in partnership with Handa Therapeutics, LLC. Handa developed the product and granted Cycle an exclusive U.S. sales license. PHYRAGO is a tyrosine kinase inhibitor for Ph+ CML and Ph+ ALL, bioequivalent to Sprycel with improved PPI/H2RA compatibility.

cyclepharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-16
Description

Onco360 selected as the exclusive specialty pharmacy partner for PHYRAGO (dasatinib). Onco360 is the nation's largest independent Oncology Pharmacy and dispenses nationally through its URAC- and ACHC-accredited network.

5McKesson, Cencora, Cardinal Health
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-16
Description

Cycle established a specialty distribution network from McKesson, Cencora, and Cardinal Health for PHYRAGO, ensuring broad access through major pharmaceutical distributors.

cyclepharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-21
Description

Cycle awarded LeMed Specialty Pharmacy an exclusive contract for distributing HARLIKU (nitisinone) Tablets in the US, the first FDA-approved treatment for AKU. LeMed manages commercial and non-commercial dispensing.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-01
Description

Cycle acquired Banner Life Sciences, a U.S. company offering BAFIERTAM (monomethyl fumarate) for relapsing forms of multiple sclerosis, strengthening Cycle's neurological disorder portfolio in the U.S. market. BAFIERTAM became part of Cycle's product portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Partnership between Cycle and Torrent Pharma for tiopronin delayed-release tablets (VENXXIVA) and ORMALVI (dichlorphenamide). Torrent supplies the products while Cycle handles US commercialization and patient support via Cycle Vita.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-07
Description

Anovo serves as the exclusive specialty pharmacy for tiopronin delayed-release tablets, providing end-to-end services including specialty wholesale/distribution, specialty pharmacy services, and patient support hub programs.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-15
Description

Cycle partnered with Inceptua to provide its Free Goods Programme for patients with HT-1 and AKU in 15 countries where rare disease medication is unaffordable. Inceptua handles the logistics and compliance of making nitisinone available under the Special Access Scheme.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-03
Description

Established partnership between Cycle and Dr Reddy's for JAVYGTOR (sapropterin dihydrochloride) for PKU treatment. Cycle commercializes the product in the US while Dr Reddy's manufactures and supplies. Both companies are committed to providing affordable medicines to rare disease patients.

12AKU Society
Strategic tierCoreTypeOthers
Description

Cycle works collaboratively with the AKU Society, a global patient advocacy group supporting patients and families with Alkaptonuria, funding research, and helping patients access HARLIKU treatment.

cyclepharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established rare disease biopharma with a broader portfolio of branded therapeutics for rare conditions. Comparable as a larger incumbent in the rare disease space with similar commercial and patient support infrastructure.

TypeDirect peer
Description

Specialty pharmaceutical company focused on rare diseases across metabolic, endocrine, and oncology indications. Directly comparable to Cycle in its strategy of acquiring, reformulating, and commercializing treatments for rare disease patients through specialty channels.

TypeDirect peer
Description

Rare disease biopharma developing and commercializing therapies for rare and ultra-rare genetic diseases. Directly comparable to Cycle's rare metabolic and neurological disease focus areas and orphan drug commercialization approach.

TypeBroad incumbent
Description

Larger rare disease franchise within AstraZeneca focused on rare neurological, metabolic, and immunological conditions. Comparable as a broad incumbent operating in overlapping rare disease therapeutic areas with Cycle's immunology and metabolic portfolio.

TypeBroad incumbent
Description

Specialty biopharma with significant focus on rare diseases across immunology, hematology, and metabolic indications. Comparable to Cycle's strategy of addressing rare disease patient communities through specialized products and support services.

TypeBroad incumbent
Description

Specialty pharmaceutical company with franchises in neurology and oncology rare diseases. Comparable to Cycle's specialty pharmacy distribution model and focus on conditions with limited treatment options.

TypeDirect peer
Description

Rare disease specialty pharma that developed and commercialized treatments for rare and ultra-rare conditions, including metabolic diseases. Comparable to Cycle's rare metabolic disease focus and reformulation approach before its acquisition.

TypeOthers
Description

Major generics manufacturer and Cycle's manufacturing partner for JAVYGTOR. Comparable to Cycle as a partnership counterparty in the rare disease generic/specialty space and as a relevant scale reference for global pharmaceutical supply.

9Horizon Therapeutics (Amgen)
TypeBroad incumbent
Description

Rare disease specialty pharma (now part of Amgen) with focus on rare inflammatory, autoimmune, and metabolic diseases. Comparable to Cycle's specialty distribution model and therapeutic diversity across rare conditions.

TypeEmerging player
Description

Emerging specialty pharma focused on rare disease product development and commercialization. Comparable to Cycle as a smaller, growth-oriented rare disease player pursuing commercial launches in underserved indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cycle Pharmaceuticals

Specialty Pharmaceuticals (Rare Disease)cyclepharma.com

Cycle Pharmaceuticals is a UK-headquartered rare disease pharmaceutical company founded in 2012 that develops and commercializes 10 FDA-approved treatments across oncology, neurology, metabolics, and immunology, distributed via US specialty pharmacy networks and supported by the Cycle Vita patient hub.

What Cycle Pharmaceuticals does

Cycle Pharmaceuticals is a UK-headquartered, privately-held specialty pharmaceutical company founded in 2012 by James Harrison to develop and commercialize treatments for rare and ultra-rare diseases. The company operates from Cambridge, UK, with US offices in Detroit and Boston, and employs over 100 people across multiple nationalities. Cycle has assembled a portfolio of 10 FDA-approved products spanning oncology (PHYRAGO/dasatinib, CAVHANZA/nilotinib ODT), neurology (TASCENSO ODT/fingolimod, BAFIERTAM/monomethyl fumarate), metabolics (NITYR/nitisinone, HARLIKU/nitisinone, JAVYGTOR/sapropterin), immunology (SAJAZIR/icatibant), and urology/nephrology (VENXXIVA/tiopronin, ORMALVI/dichlorphenamide).

Cycle's core technical capability is drug reformulation — applying technologies including orally disintegrating tablet (ODT) formulations via Catalent's ZYDIS platform and Flex Pharma's ElectroNanoSpray (ENS) platform to improve form factor, swallowability, and co-medication compatibility (notably acid-reducing agent compatibility for TKIs). The company's commercial model relies on US specialty pharmacy distribution through exclusive partners (Onco360, LeMed, Anovo) and the three major US pharmaceutical distributors (McKesson, Cencora, Cardinal Health). Patient engagement is anchored by the Cycle Vita support hub providing financial, clinical, and adherence services, supplemented by the AI-enabled Cycle Vita PKU app. Internationally, Cycle operates a Free Goods Programme in 15 countries via partner Inceptua, embedding patient access in the company's constitutional documents. Recent M&A (Banner Life Sciences in January 2025, Applied Therapeutics in February 2026) has expanded the neurology and CNS rare metabolic disease franchises respectively.

Cycle Pharmaceuticals firmographics

Firmographics
Name
Cycle Pharmaceuticals
Legal name
Cycle Pharmaceuticals Limited
Website
https://cyclepharma.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Cycle Pharmaceuticals is a UK-headquartered rare disease pharmaceutical company founded in 2012 that develops and commercializes 10 FDA-approved treatments across oncology, neurology, metabolics, and immunology, distributed via US specialty pharmacy networks and supported by the Cycle Vita patient hub.
Ownership category
akta.pro rank

Cycle Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals (Rare Disease)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Rare disease pharmaceuticals
  • Specialty pharma distribution
  • Orally disintegrating tablets
  • Patient support services
  • Branded drug reformulation

Where Cycle Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Cycle Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Cycle Pharmaceuticals generates revenue through the sale of FDA-approved pharmaceutical products for rare diseases and oncology. The company commercializes branded drugs across multiple therapeutic areas (metabolic, immunological, neurological, oncology) through specialty pharmacy distribution networks in the US market, complemented by patient support programs.
  2. Free Goods Programme: Cycle operates a Free Goods Programme (Special Access Scheme/Compassionate Use Programme) providing nitisinone to patients with HT-1 and AKU in countries where they are unlikely to have means to pay, at no cost to patients. This is embedded in the company's constitutional documents and represents a non-revenue charitable program.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Cycle Pharmaceuticals product offering

Product offering

Core offering

Cycle Pharmaceuticals develops, reformulates, and commercializes FDA-approved pharmaceutical products for rare and ultra-rare diseases across oncology, neurology, metabolics, and immunology. The company distributes branded therapies (e.g., NITYR, HARLIKU, PHYRAGO, CAVHANZA, TASCENSO ODT, BAFIERTAM, SAJAZIR, JAVYGTOR, ORMALVI, VENXXIVA) through specialty pharmacy networks in the US and supplements its commercial offering with the Cycle Vita patient support programme and an international Free Goods Programme.

Product overview

Cycle Pharmaceuticals is a rare disease-focused pharmaceutical company offering a portfolio of treatments across oncology, neurology/metabolics, immunology, and urology. The company operates as a single-brand pharmaceutical manufacturer with patient support services. Core products include NITYR (nitisinone) for HT-1, SAJAZIR (icatibant) for HAE, JAVYGTOR (sapropterin) for PKU, TASCENSO ODT (fingolimod) for MS, BAFIERTAM (monomethyl fumarate) for MS, ORMALVI (dichlorphenamide) for periodic paralysis, VENXXIVA (tiopronin) for cystinuria, and HARLIKU (nitisinone) for AKU. In oncology, the portfolio includes PHYRAGO (dasatinib) for Ph+ leukemias and CAVHANZA (nilotinib) for Ph+ CML. The company also provides the Cycle Vita™ patient support platform including a PKU management app. Following the 2026 acquisition of Applied Therapeutics, the pipeline expanded to include govorestat for CNS rare metabolic diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • Cycle Vita: Patient support programme for patients in the US providing individualized emotional, financial, and product support.
  • Cycle Vita PKU

Products and services

  • PHYRAGO (dasatinib) Tablets Tyrosine kinase inhibitor tablet for adults and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). Bioequivalent to Sprycel with the unique clinical benefit of allowing co-administration with proton pump inhibitors and H2 receptor antagonists.
  • CAVHANZA (nilotinib) Orally Disintegrating Tablets Orally disintegrating kinase inhibitor tablet for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed adults in chronic phase and adults with chronic and accelerated phase Ph+ CML resistant or intolerant to prior therapy including imatinib. First nilotinib formulation allowing co-administration with acid-reducing agents without timing restrictions, using Flex Pharma's ElectroNanoSpray technology for improved solubility and dissolution.
  • HARLIKU (nitisinone) Tablets First and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients with alkaptonuria (AKU/Black Bone Disease). Reduces urinary HGA production by up to 97% through enzyme inhibition.
  • BAFIERTAM (monomethyl fumarate) Delayed-Release Capsules Disease-modifying therapy for relapsing forms of multiple sclerosis. A unique fumarate agent requiring no dietary restrictions and no metabolic conversion, acquired from Banner Life Sciences.
  • TASCENSO ODT (fingolimod) Sphingosine 1-phosphate receptor modulator for relapsing forms of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. First orally disintegrating tablet for MS patients, using Catalent ZYDIS technology.
  • VENXXIVA (tiopronin) Delayed-Release Tablets Reducing and complexing thiol for prevention of cystine stone formation in patients with severe homozygous cystinuria. Available in 100mg and 300mg doses, to be taken without food.
  • ORMALVI (dichlorphenamide) Tablets Oral carbonic anhydrase inhibitor for treatment of primary hyperkalemic periodic paralysis (HyperPP), hypokalemic periodic paralysis (HypoPP), and related variants.
  • SAJAZIR (icatibant) Injection Bradykinin B2 receptor antagonist for treatment of acute attacks of hereditary angioedema (HAE) in adults 18+. Self-administered subcutaneous injection delivering 30mg icatibant.
  • JAVYGTOR (sapropterin dihydrochloride) Treatment to reduce blood phenylalanine levels in patients with tetrahydrobiopterin-responsive Phenylketonuria (PKU). Available as 100mg tablets and 100mg/500mg powder for oral solution, used in conjunction with a Phe-restricted diet.
  • NITYR (nitisinone) Tablets Treatment for Hereditary Tyrosinemia Type 1 (HT-1), Cycle's original commercial product launched in 2017 and updated in 2018 for infant administration dosing.
  • Cycle Vita Patient Support Program Comprehensive patient support hub providing individualized emotional, financial, and product support for patients on Cycle medications, including co-pay assistance, bridge programs, registered dietitian nutrition support, and the Cycle Vita PKU mobile app.
  • Cycle Vita PKU Mobile App Smartphone application for PKU management featuring medication and lab result tracking, diet management tools, and an AI-powered meal scanner for food identification and nutritional analysis. Available on iOS App Store and Google Play.

Quantifiable outcome

  • HARLIKU (nitisinone) reduces urinary homogentisic acid (HGA) production by up to 97% in AKU patients
  • +3 more outcomes

Companies that use Cycle Pharmaceuticals

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Cycle Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Cycle Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core.

  • Flex PharmacoreStrategic or Co-development Partner · 2 June 2026Cycle partnered with Flex Pharma for CAVHANZA (nilotinib) ODT formulation. Flex contributed its proprietary ElectroNanoSpray (ENS) platform technology to develop an improved nilotinib formulation with maintained bioavailability when taken with acid-reducing agents, addressing a significant unmet need in CML treatment.
  • Applied Therapeutics, Inc.coreOEM/ Whitelabel/ Licensing Partner · 3 February 2026Cycle completed the acquisition of Applied Therapeutics, a NASDAQ-listed clinical-stage biopharma focused on rare metabolic diseases. Applied's lead drug candidate govorestat (CNS-penetrant Aldose Reductase Inhibitor) targets Classic Galactosemia, CMT-SORD, and PMM2-CDG. The all-cash transaction was funded from Cycle's existing cash reserves.
  • Handa Therapeutics, LLCcoreStrategic or Co-development Partner · 16 October 2025Cycle launched PHYRAGO (dasatinib) tablets in partnership with Handa Therapeutics, LLC. Handa developed the product and granted Cycle an exclusive U.S. sales license. PHYRAGO is a tyrosine kinase inhibitor for Ph+ CML and Ph+ ALL, bioequivalent to Sprycel with improved PPI/H2RA compatibility.
  • Onco360coreChannel Partner/ Reseller/ Distributor · 16 October 2025Onco360 selected as the exclusive specialty pharmacy partner for PHYRAGO (dasatinib). Onco360 is the nation's largest independent Oncology Pharmacy and dispenses nationally through its URAC- and ACHC-accredited network.
  • McKesson, Cencora, Cardinal HealthcoreChannel Partner/ Reseller/ Distributor · 16 October 2025Cycle established a specialty distribution network from McKesson, Cencora, and Cardinal Health for PHYRAGO, ensuring broad access through major pharmaceutical distributors.
  • LeMed Specialty PharmacycoreChannel Partner/ Reseller/ Distributor · 21 July 2025Cycle awarded LeMed Specialty Pharmacy an exclusive contract for distributing HARLIKU (nitisinone) Tablets in the US, the first FDA-approved treatment for AKU. LeMed manages commercial and non-commercial dispensing.
  • Banner Life Sciences, LLCcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Cycle acquired Banner Life Sciences, a U.S. company offering BAFIERTAM (monomethyl fumarate) for relapsing forms of multiple sclerosis, strengthening Cycle's neurological disorder portfolio in the U.S. market. BAFIERTAM became part of Cycle's product portfolio.
  • Torrent Pharma Inc.coreStrategic or Co-development Partner · 7 May 2024Partnership between Cycle and Torrent Pharma for tiopronin delayed-release tablets (VENXXIVA) and ORMALVI (dichlorphenamide). Torrent supplies the products while Cycle handles US commercialization and patient support via Cycle Vita.
  • Anovo Specialty PharmacycoreChannel Partner/ Reseller/ Distributor · 7 May 2024Anovo serves as the exclusive specialty pharmacy for tiopronin delayed-release tablets, providing end-to-end services including specialty wholesale/distribution, specialty pharmacy services, and patient support hub programs.
  • Inceptua GroupcoreChannel Partner/ Reseller/ Distributor · 15 January 2024Cycle partnered with Inceptua to provide its Free Goods Programme for patients with HT-1 and AKU in 15 countries where rare disease medication is unaffordable. Inceptua handles the logistics and compliance of making nitisinone available under the Special Access Scheme.
  • Dr Reddy's Laboratories LtdcoreStrategic or Co-development Partner · 3 October 2022Established partnership between Cycle and Dr Reddy's for JAVYGTOR (sapropterin dihydrochloride) for PKU treatment. Cycle commercializes the product in the US while Dr Reddy's manufactures and supplies. Both companies are committed to providing affordable medicines to rare disease patients.
  • AKU SocietycoreOthersCycle works collaboratively with the AKU Society, a global patient advocacy group supporting patients and families with Alkaptonuria, funding research, and helping patients access HARLIKU treatment.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Cycle Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biopharma with a broader portfolio of branded therapeutics for rare conditions. Comparable as a larger incumbent in the rare disease space with similar commercial and patient support infrastructure.
  • Alexion (AstraZeneca Rare Disease): Larger rare disease franchise within AstraZeneca focused on rare neurological, metabolic, and immunological conditions. Comparable as a broad incumbent operating in overlapping rare disease therapeutic areas with Cycle's immunology and metabolic portfolio.
  • Swedish Orphan Biovitrum (Sobi): Specialty biopharma with significant focus on rare diseases across immunology, hematology, and metabolic indications. Comparable to Cycle's strategy of addressing rare disease patient communities through specialized products and support services.
  • Jazz Pharmaceuticals: Specialty pharmaceutical company with franchises in neurology and oncology rare diseases. Comparable to Cycle's specialty pharmacy distribution model and focus on conditions with limited treatment options.
  • Horizon Therapeutics (Amgen): Rare disease specialty pharma (now part of Amgen) with focus on rare inflammatory, autoimmune, and metabolic diseases. Comparable to Cycle's specialty distribution model and therapeutic diversity across rare conditions.

Direct peers

  • Recordati Rare Diseases: Specialty pharmaceutical company focused on rare diseases across metabolic, endocrine, and oncology indications. Directly comparable to Cycle in its strategy of acquiring, reformulating, and commercializing treatments for rare disease patients through specialty channels.
  • Ultragenyx Pharmaceutical: Rare disease biopharma developing and commercializing therapies for rare and ultra-rare genetic diseases. Directly comparable to Cycle's rare metabolic and neurological disease focus areas and orphan drug commercialization approach.
  • Amryt Pharma (acquired by Chiesi): Rare disease specialty pharma that developed and commercialized treatments for rare and ultra-rare conditions, including metabolic diseases. Comparable to Cycle's rare metabolic disease focus and reformulation approach before its acquisition.

Others

  • Dr Reddy's Laboratories: Major generics manufacturer and Cycle's manufacturing partner for JAVYGTOR. Comparable to Cycle as a partnership counterparty in the rare disease generic/specialty space and as a relevant scale reference for global pharmaceutical supply.

Emerging players

  • Eton Pharmaceuticals: Emerging specialty pharma focused on rare disease product development and commercialization. Comparable to Cycle as a smaller, growth-oriented rare disease player pursuing commercial launches in underserved indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Cycle Pharmaceuticals social profiles

Digital presence

Cycle Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cycle Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Cycle Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Cycle Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cycle Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cycle Pharmaceuticals

What does Cycle Pharmaceuticals do?

Cycle Pharmaceuticals develops, reformulates, and commercializes FDA-approved pharmaceutical products for rare and ultra-rare diseases across oncology, neurology, metabolics, and immunology. The company distributes branded therapies (e.g., NITYR, HARLIKU, PHYRAGO, CAVHANZA, TASCENSO ODT, BAFIERTAM, SAJAZIR, JAVYGTOR, ORMALVI, VENXXIVA) through specialty pharmacy networks in the US and supplements its commercial offering with the Cycle Vita patient support programme and an international Free Goods Programme.

Is Cycle Pharmaceuticals a public or private company?

Cycle Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cycle Pharmaceuticals founded?

Cycle Pharmaceuticals was founded in 2012. It employs 51 to 100 people.

Where is Cycle Pharmaceuticals based?

Cycle Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

How does Cycle Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are free Goods Programme.

Who are Cycle Pharmaceuticals's main competitors?

Broad incumbents on record are BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease), Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals and Horizon Therapeutics (Amgen). Direct peers are Recordati Rare Diseases, Ultragenyx Pharmaceutical and Amryt Pharma (acquired by Chiesi). Dr Reddy's Laboratories is listed as an others. Eton Pharmaceuticals is listed as an emerging player.

Does Cycle Pharmaceuticals have an API?

No public API is recorded for Cycle Pharmaceuticals.

What industry is Cycle Pharmaceuticals in?

Cycle Pharmaceuticals's product category is Specialty Pharmaceuticals (Rare Disease). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIABAA, Small-Molecule Generics (Branded/Unbranded). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCycle Pharmaceuticals launches CAVHANZA™ (nilotinib) Orally Disintegrating Tablets (ODT), designed for use with PPIs and H₂RAs without food restrictions1Cycle Pharmaceuticals announced on August 24, 2026 the U.S. launch of CAVHANZA, an orally disintegrating tablet formulation of nilotinib developed in partnership with Flex Pharma for Philadelphia chromosome-positive chronic myeloid leukemia. The company said it is 60% lower in milligram strength than Tasigna, can be taken with or without food or water, and works alongside PPIs and H2RAs without timing restrictions. No pricing or commercial details were disclosed.OcbjForma Life Sciences Wins U.S. Drug Supply DealForma Life Sciences has been selected by Cycle Pharmaceuticals to manufacture and supply an FDA-approved treatment for chronic myeloid leukemia in the U.S. Under the agreement, Forma will produce oral tablets at its Irvine facilities as Cycle prepares to introduce the product to the American market.FinancialContent Business PageCycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating TabletsCycle Pharmaceuticals and Forma Life Sciences have entered a commercial manufacturing agreement for CAVHANZA, an FDA-approved treatment for Philadelphia chromosome-positive chronic myeloid leukemia. Under the deal, Forma will manufacture the drug at its Irvine, California facility to establish a U.S. commercial supply as Cycle prepares for market introduction.Business Wire BlogCycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating TabletsCycle Pharmaceuticals and Forma Life Sciences announced a commercial manufacturing agreement for CAVHANZA™ (nilotinib) orally disintegrating tablets, with Forma set to manufacture the drug at its Irvine, California facility. This partnership establishes a U.S. commercial supply chain as Cycle prepares to launch the FDA-approved treatment for Philadelphia chromosome-positive chronic myeloid leukemia in the United States market.MorningstarCycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating TabletsCycle Pharmaceuticals and Forma Life Sciences announced a commercial manufacturing agreement for CAVHANZA, an FDA-approved nilotinib orally disintegrating tablet for Philadelphia chromosome-positive chronic myeloid leukemia. Forma will manufacture the product at its Irvine, California facilities, establishing U.S. commercial supply as Cycle prepares to introduce it to the U.S. market.Business Wire BlogCAVHANZA™ (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients1Cycle Pharmaceuticals announced FDA approval of CAVHANZA (nilotinib) orally disintegrating tablets, launching soon. The formulation improves solubility and dissolution, allowing use with PPIs or H2RAs without timing restrictions, addressing a challenge in Ph+ CML treatment where 25% of patients are co-prescribed acid-reducing agents.openPR.comGlobal Drivers Analysis: The Rapid Evolution of the Relapsing-Remitting Multiple Sclerosis MarketThe relapsing-remitting multiple sclerosis (RRMS) market is projected to grow from its current valuation to $6.02 billion by 2030, representing a compound annual growth rate of 4.6%, driven by next-generation therapies, precision medicine adoption, and expanded oral treatment options. In January 2025, UK-based Cycle Pharmaceuticals Ltd. acquired Banner Life Sciences, a U.S. company offering BAFIERTAM for relapsing forms of multiple sclerosis, a transaction expected to strengthen Cycle Pharmaceuticals' neurological disorder portfolio in the U.S. market. Additionally, Roche Products (India) launched Ocrevus (Ocrelizumab) in February 2024, a therapy targeting CD20-positive B cells to reduce relapse frequency and slow disability advancement in MS patients.HrtodayCheryl Lee Appointed as Head of Compliance at Cycle PharmaceuticalsCheryl Lee has been appointed Head of Compliance at Cycle Pharmaceuticals, where she will lead the company's Global and U.S. Healthcare Compliance and Privacy Program, strengthening governance and regulatory adherence. Lee joins from Bristol Myers Squibb, where she most recently served as Vice President of ESG Strategy and Execution, bringing extensive compliance expertise from prior leadership roles at Celgene, Pfizer, and Ernst & Young. Cycle Pharmaceuticals, headquartered in Cambridge, UK with U.S. operations, specializes in treatments for neurological, rare metabolic, rare immunological, and rare leukemia conditions.FiercePharmaSpruce hooks a commercial chief to prep for rare disease launchSpruce Biosciences has appointed Dale Hooks as Chief Commercial Officer, bringing experience launching 21 products as the company pursues its first FDA approval filing for tralesinidase alfa enzyme replacement therapy (TA-ERT) targeting Sanfilippo syndrome type B. Hooks joins from Applied Therapeutics, where he was among executives terminated following Cycle Pharmaceuticals' acquisition of the company. Spruce recently received guidance from the FDA on a pathway to accelerated approval and forecasts approximately 500 patients each in the U.S. and globally at peak for the rare disease treatment.BioSpaceCycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsCycle Group Holdings Limited has completed its acquisition of NASDAQ-listed Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare metabolic diseases. The all-cash transaction brings Applied's lead drug candidate govorestat into Cycle's portfolio—a CNS-penetrant Aldose Reductase Inhibitor targeting conditions including Classic Galactosemia, CMT-SORD, and PMM2-CDG, for which no FDA-approved treatments currently exist. Cycle, which was founded to serve the underserved rare disease community, stated the acquisition will support its expansion in this therapeutic area.